The role of germline BRCA1 & BRCA2 mutations in familial pancreatic cancer: A systematic review and meta-analysis
PLOS ONE · 29.05.2024 · 19 (5) · e0299276
DOI: 10.1371/journal.pone.0299276 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift PLOS ONE, online erschienen am 29.05.2024. Verfasst von Edward Kurnia Setiawan Limijadi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral Study Program of Medical and Health Science, Universitas Diponegoro, Semarang, Indonesia. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Germ-Line Mutation, BRCA2 Protein, BRCA1 Protein. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Familial Pancreatic Cancer (FPC) presents a notable risk, with 3–10% of pancreatic adenocarcinoma cases having a family history. Studies link FPC to syndromes like HBOC, suggesting BRCA1/BRCA2 mutations play a role. BRCA gene functions in DNA repair impact FPC management, influencing sensitivity to therapies like PARP inhibitors. Identifying mutations not only aids FPC treatment but also reveals broader cancer risks. However, challenges persist in selectively applying genetic testing due to cost constraints. This Systematic Review focuses on BRCA1/BRCA2 significance in FPC, diagnostic criteria, prognostic value, and limitations.
Method
Original articles published from 2013 to January 2023 were sourced from databases such as Scopus, PubMed, ProQuest, and ScienceDirect. Inclusion criteria comprised observational cohort or diagnostic studies related to the role of BRCA1/2 mutation in correlation to familial pancreatic cancer (FPC), while article reviews, narrative reviews, and non-relevant content were excluded. The assessment of bias used ROBINS-I, and the results were organized using PICOS criteria in a Google spreadsheet table. The systematic review adhered to the PRISMA 2020 checklist.
Result
We analyzed 9 diagnostic studies encompassing 1325 families and 4267 patients from Italy, USA, and Poland. Despite the limitation of limited homogenous PICO studies, our findings effectively present evidence. BRCA1/2 demonstrates benefits in detecting first-degree relatives FPC involvement with 2.26–10 times higher risk. These mutation findings also play an important role since with the BRCA1/2 targeted therapy, Poly-ADP Ribose Polymerase inhibitors (PARP) may give better outcomes of FPC treatment. Analysis of BRCA1 and BRCA2 administration’s impact on odds ratio (OR) based on six and five studies respectively. BRCA1 exhibited non-significant effects (OR = 1.26, P = 0.51), while BRCA2 showed significance (OR = 1.68, P = 0.04). No heterogeneity observed, indicating consistent results. Further research on BRCA1 is warranted.
Conclusion
Detecting the BRCA1/2 mutation gene offers numerous advantages, particularly in its correlation with FPC. For diagnostic and prognostic purposes, testing is strongly recommended for first-degree relatives, who face a significantly higher risk (2.26–10 times) of being affected. Additionally, FPC patients with identified BRCA1/2 mutations exhibit a more favorable prognosis compared to the non-mutated population. This is attributed to the availability of targeted BRCA1/2 therapy, which maximizes treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Doctoral Study Program of Medical and Health Science, Universitas Diponegoro, Semarang, Indonesia.
- Faculty of Medicine, Department of Clinical Pathology, Universitas Diopnegoro, Semarang, Indonesia.
- Faculty of Medicine, Department of Physiology, Universitas Diponegoro, Semarang, Indonesia.
- Faculty of Medicine, Department of Surgical Oncology, Universitas Diponegoro, Semarang, Indonesia.
- Kariadi General Hospital, Semarang, Indonesia.
- Faculty of Medicine, Departement of Medicine, Universitas Diponegoro, Semarang, Indonesia.
ORCID-Profile: Edward Kurnia Setiawan Limijadi, Kevin Christian Tjandra, Danendra Rakha Putra Respati
Zitieren
APA
Limijadi, E. K. S., Muniroh, M., Prajoko, Y. W., Tjandra, K. C., & Respati, D. R. P. (2024). The role of germline BRCA1 & BRCA2 mutations in familial pancreatic cancer: A systematic review and meta-analysis. PLOS ONE, 19(5), e0299276. https://doi.org/10.1371/journal.pone.0299276
Vancouver
Limijadi EKS, Muniroh M, Prajoko YW, Tjandra KC, Respati DRP. The role of germline BRCA1 & BRCA2 mutations in familial pancreatic cancer: A systematic review and meta-analysis. PLOS ONE. 2024;19(5):e0299276. doi:10.1371/journal.pone.0299276
BibTeX
@article{Limijadi2024,
author = {Limijadi, Edward Kurnia Setiawan and Muniroh, Muflihatul and Prajoko, Yan Wisnu and Tjandra, Kevin Christian and Respati, Danendra Rakha Putra},
title = {The role of germline BRCA1 & BRCA2 mutations in familial pancreatic cancer: A systematic review and meta-analysis},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {5},
pages = {e0299276},
doi = {10.1371/journal.pone.0299276}
}
EUVIMED